These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 26276764)
1. Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors. Smith DE; Marquez I; Lokensgard ME; Rheingold AL; Hecht DA; Gustafson JL Angew Chem Int Ed Engl; 2015 Sep; 54(40):11754-9. PubMed ID: 26276764 [TBL] [Abstract][Full Text] [Related]
2. Atropisomerism in the Pharmaceutically Relevant Realm. Basilaia M; Chen MH; Secka J; Gustafson JL Acc Chem Res; 2022 Oct; 55(20):2904-2919. PubMed ID: 36153960 [TBL] [Abstract][Full Text] [Related]
3. Atropisomerism in medicinal chemistry: challenges and opportunities. Toenjes ST; Gustafson JL Future Med Chem; 2018 Feb; 10(4):409-422. PubMed ID: 29380622 [TBL] [Abstract][Full Text] [Related]
4. Atropisomerism in Drug Discovery: A Medicinal Chemistry Perspective Inspired by Atropisomeric Class I PI3K Inhibitors. Perreault S; Chandrasekhar J; Patel L Acc Chem Res; 2022 Sep; 55(18):2581-2593. PubMed ID: 36069734 [TBL] [Abstract][Full Text] [Related]
5. Approaches to Synthesis and Isolation of Enantiomerically Pure Biologically Active Atropisomers. Carlsson AC; Karlsson S; Munday RH; Tatton MR Acc Chem Res; 2022 Oct; 55(20):2938-2948. PubMed ID: 36194144 [TBL] [Abstract][Full Text] [Related]
6. The role of chromatographic and chiroptical spectroscopic techniques and methodologies in support of drug discovery for atropisomeric drug inhibitors of Bruton's tyrosine kinase. Dai J; Wang C; Traeger SC; Discenza L; Obermeier MT; Tymiak AA; Zhang Y J Chromatogr A; 2017 Mar; 1487():116-128. PubMed ID: 28131592 [TBL] [Abstract][Full Text] [Related]
7. Recent encounters with atropisomerism in drug discovery. Glunz PW Bioorg Med Chem Lett; 2018 Jan; 28(2):53-60. PubMed ID: 29223590 [TBL] [Abstract][Full Text] [Related]
8. Atropisomerism transforming anti-cancer drug discovery. Patel S; Sandha K; Waingankar A; Jain P; Abhyankar A Chem Biol Drug Des; 2023 Jan; 101(1):138-157. PubMed ID: 36254625 [TBL] [Abstract][Full Text] [Related]
9. Revealing atropisomer axial chirality in drug discovery. LaPlante SR; Edwards PJ; Fader LD; Jakalian A; Hucke O ChemMedChem; 2011 Mar; 6(3):505-13. PubMed ID: 21360821 [TBL] [Abstract][Full Text] [Related]
10. Recent progress toward developing axial chirality bioactive compounds. Wang Z; Meng L; Liu X; Zhang L; Yu Z; Wu G Eur J Med Chem; 2022 Dec; 243():114700. PubMed ID: 36058089 [TBL] [Abstract][Full Text] [Related]
11. Establishment of atropisomerism in 3-indolyl furanoids: a synthetic, experimental and theoretical perspective. Chatterjee S; Bhattacharjee P; Butterfoss GL; Achari A; Jaisankar P RSC Adv; 2019 Jul; 9(39):22384-22388. PubMed ID: 35519481 [TBL] [Abstract][Full Text] [Related]
12. Separation of triphenyl atropisomers of a pharmaceutical compound on a novel mixed mode stationary phase: a case study involving dynamic chromatography, dynamic NMR and molecular modeling. Bu X; Skrdla PJ; Dormer PG; Bereznitski Y J Chromatogr A; 2010 Nov; 1217(46):7255-64. PubMed ID: 20947090 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and atropisomerism of iron complexes containing the tetrakis(2-chloro-6-fluorophenyl)porphyrinate ligand. Meininger DJ; Muzquiz N; Arman HD; Tonzetich ZJ Dalton Trans; 2015 May; 44(20):9486-95. PubMed ID: 25915442 [TBL] [Abstract][Full Text] [Related]
14. Single cell network profiling (SCNP): mapping drug and target interactions. Covey TM; Putta S; Cesano A Assay Drug Dev Technol; 2010 Jun; 8(3):321-43. PubMed ID: 20158439 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N: unique effects of the axial chirality on the selectivity of protein kinases inhibition. Yoshida K; Itoyama R; Yamahira M; Tanaka J; Loaëc N; Lozach O; Durieu E; Fukuda T; Ishibashi F; Meijer L; Iwao M J Med Chem; 2013 Sep; 56(18):7289-301. PubMed ID: 23981088 [TBL] [Abstract][Full Text] [Related]
16. Atropisomerism - A Neglected Way to Escape Out of Solubility Flatlands. Saal C; Becker A; Krier M; Fuchß T J Pharm Sci; 2022 Jan; 111(1):206-213. PubMed ID: 34662544 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity. Voss ME; Rainka MP; Fleming M; Peterson LH; Belanger DB; Siddiqui MA; Hruza A; Voigt J; Gray K; Basso AD Bioorg Med Chem Lett; 2012 May; 22(10):3544-9. PubMed ID: 22503250 [TBL] [Abstract][Full Text] [Related]
19. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Hasinoff BB; Patel D Toxicol Appl Pharmacol; 2010 Dec; 249(2):132-9. PubMed ID: 20832415 [TBL] [Abstract][Full Text] [Related]
20. Simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist. Zhou YS; Tay LK; Hughes D; Donahue S J Clin Pharmacol; 2004 Jul; 44(7):680-8. PubMed ID: 15199072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]